Diabetic retinopathy (DR) is the leading cause of blindness in people of working age. The purpose of this paper is to report the prevalence and cardiovascular associations of diabetic retinopathy and maculopathy (DMac) in Germany.
Research Design and Methods
The Gutenberg Health Study (GHS) is a population-based study with 15,010 participants aged between 35 at 74 years from the city of Mainz and the district of Mainz-Bingen. We determined the weighted prevalence of DR and DMac by assessing fundus photographs of persons with diabetes from the GHS data base. Diabetes was defined as HbA1c ≥ 6.5%, known diagnosis diabetes mellitus or known diabetes medication. Furthermore, we analysed the association between DR and cardiovascular risk factors and diseases.
Overall, 7.5% (1,124/15,010) of the GHS cohort had diabetes. Of these, 27.7% were unaware of their disease and thus were newly diagnosed by their participation in the GHS. The prevalence of DR and DMac was 21.7% and 2.3%, respectively among patients with diabetes. Vision-threatening disease was present in 5% of the diabetic cohort. In the multivariable analysis DR (all types) was associated with age (Odds Ratio [95% confidence interval]: 0.97 [0.955–0.992]; p = 0.006) arterial hypertension (1.90 [1.190–3.044]; p = 0.0072) and vision-threatening DR with obesity (3.29 [1.504–7.206]; p = 0.0029). DR (all stages) and vision-threatening DR were associated with duration of diabetes (1.09 [1.068–1.114]; p<0.0001 and 1.18 [1.137–1.222]; p<0.0001, respectively).
Our calculations suggest that more than a quarter-million persons have vision-threatening diabetic retinal disease in Germany. Prevalence of DR was lower in the GHS compared to East-Asian studies. Associations were found with age, arterial hypertension, obesity, and duration of diabetes mellitus.
Citation: Raum P, Lamparter J, Ponto KA, Peto T, Hoehn R, Schulz A, et al. (2015) Prevalence and Cardiovascular Associations of Diabetic Retinopathy and Maculopathy: Results from the Gutenberg Health Study. PLoS ONE 10(6): e0127188. https://doi.org/10.1371/journal.pone.0127188
Academic Editor: Neena B. Haider, Schepens Eye Research Institute/Massachusetts Eye and Ear, Department of Ophthalmology, Harvard Medical School, Boston, MA, UNITED STATES
Received: October 2, 2014; Accepted: April 12, 2015; Published: June 15, 2015
Copyright: © 2015 Raum et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited
Data Availability: Data cannot be made available in the manuscript, the supplemental files, or in a public repository because of institutional restrictions imposed by the steering committee of the Gutenberg Health Study. Data will be made available to all interested researchers upon request. To request the data, interested researchers may contact the study manager of the Gutenberg Health Study, Christian (email@example.com).
Funding: The Gutenberg Health Study is funded through the government of Rhineland- Palatinate („Stiftung Rheinland-Pfalz für Innovation“, contract AZ 961-386261/733), the research programs “Wissen schafft Zukunft” and “Center for Translational Vascular Biology (CTVB)” as well as the Center for Thrombosis and Haemostasis (CTH) of the Johannes Gutenberg-University of Mainz, and its contract with Boehringer Ingelheim, PHILIPS Medical Systems and Novartis including an unrestricted grant for the Gutenberg Health Study. Philipp Wild and Katharina Ponto are funded by the Federal Ministry of Education and Research (BMBF 01EO1003). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
Competing interests: Boehringer Ingelheim, Philips Medical Systems and Novartis Pharma provided an unrestricted grant for the Gutenberg Health Study. No employment, consultancy, patents, products in development or marketed products to declare. This does not alter the authors’ adherence to all the PLOS ONE policies on sharing data and materials.
Diabetic retinal and macular diseases are the main cause of legal blindness in adults aged between 20 and 74 years in industrial nations [1,2]. Diabetic retinopathy (DR) is a microangiopathic complication of diabetes mellitus (DM) being associated with cardiovascular risk factors [3,4]. It has been shown that neuronal and glial alterations may precede the overt vascular changes that characterize DR [5–10].
The prevalence of DR varies considerably according to geography, patients' ethnicity, and their way of life . To date, there are no population-based data on the prevalence of diabetic retinal and macular pathologies in Germany. From a healthcare standpoint, data on the prevalence and incidence of diabetic retinopathy are an essential basis for the future planning of healthcare provision.
The Gutenberg Health Study (GHS) is a prospective, population-based interdisciplinary study being conducted by University Medical Centre in the city of Mainz and the Bingen-Mainz region; it has 15,010 participants aged between 35 and 74 years [11–13].
The aim of our investigation was to describe the prevalence of diabetic retinopathy and maculopathy in a large German cohort and to analyse their association with cardiovascular risk factors and diseases.
We recruited 15,010 participants aged between 35 and 74 years living in the city of Mainz or the region of Mainz-Bingen for the Gutenberg Gesundheitsstudie (English: Gutenberg Health Study, or GHS) (Table 1). The GHS is a prospective, monocentric, population-based cohort study designed to examine diseases of the eye, the cardiovascular system, the psyche and the immune system [11,12]. Main objectives of the ophthalmological branch of the study are to convey the prevalence and incidence of common ophthalmological risk factors and diseases as well as to investigate interdisciplinary correlations and their genetic background. The random sample is stratified 1:1 for the cohort's gender and residence (urban versus rural), and in equal proportions across four age decades. The GHS was approved by the Ethics committee of Rhineland-Palatinate. All persons gave their written informed consent prior to their inclusion in the study.
We defined a study participant as diabetic if he or she fulfilled at least one of these criteria:
- -. diabetes mellitus diagnosed by a physician
- -. known therapy for diabetes mellitus (dietetic, oral, or insulin)
- -. HbA1c ≥6,5%
We had access to photographic images of the fundus and complete examination findings of 1,045 of the 1,124 (93.0%) diabetics in the study cohort. Of those, we had to exclude 102 (9.1%) patients due to images of inadequate quality, leaving 943 assessable fundus images of the diabetics.
Fundus images, grading and cardiovascular risk factors
The fundus images were taken with a non-mydriatic fundus camera (Visucam PRO NM, Carl Zeiss AG, Jena, Germany) in a darkened room and with the pupil’s natural width. Three photographs were taken of each eye: at 30° and 45° centred on the optic nerve, and at 30° centred on the macula.
These images were all evaluated at the Reading Centre at Moorfields Eye Hospital in London, UK at a specifically-designed work station by two certified graders (PR, JL). The fundus images were the basis upon which we diagnosed diabetic retinopathy or not and if so, its stage. The stage of DR was determined according to criteria applied in the Early Treatment Diabetic Retinopathy Study  as mild, moderate, severe non-proliferative, or as proliferative diabetic retinopathy. We also assessed whether a diabetic maculopathy was present. Table 2 illustrates the simplified ETDRS criteria for the stages of DR and DMac. In the presence of
- -. severe non-proliferative diabetic retinopathy and/or
- -. proliferative diabetic retinopathy and/or
- -. diabetic maculopathy,
The baseline examinations of the GHS study participants incorporated classic cardiovascular risk factors, namely:
- -. arterial hypertension (blood pressure syst./diast. ≥140/90 as the mean from several measurements, a physician's diagnosis, or blood-pressure medications being taken),
- -. nicotine abuse (yes: current smoker, no: never, or ex-smoker)
- -. overweight (BMI ≥ 30kg/m2)
- -. family disposition for myocardial infarction (coronary heart disease among the patient's immediate relatives before age 60 (m) or 65 (w))
- -. dyslipidaemia (presence or a physician-verified lipid-metabolism disorder (self-reported), LDL/HDL ratio).
Taking the participants' histories we also investigated whether gender, age, presence of peripheral arterial occlusive disease, atrial fibrillation, chronic heart or renal insufficiency, coronary heart disease, and previous stroke or heart attack were associated with the diagnosis of diabetic retinopathy.
For quality-control purposes we had the fundus images of 218 age and gender-matched controls assessed who did not have diabetes.
Prevalences are given as relative numbers in percent. Continuous variables are given as the mean and standard deviation, or as the median with 25–75 percentiles
We determined the weighted, gender- and age-specific prevalences of diabetic retinopathy and maculopathy as well as of any vision-threatening disease. As our study participants were stratified across gender and four age decades in equal proportions, they were weighted according to their actual age and gender distribution in their region. Weighting was based on census data as of 31.12.2009, coinciding approximately with the midpoint in our recruitment phase. As the distribution of missing values was not age- and gender-independent, weighting was done after having removed them.
Via the logistic regression model we determined whether the presence of DR was associated with age and sex and with the cardiovascular diseases and risk factors, as well as with the duration of diabetes in these individuals. We also examined whether the presence of vision-threatening disease stage was associated with those systemic diseases. A univariable binary logistic regression was performed to first show a crude odds ratio. A confounder adjusted odds ratio was calculated in a multivariable binary logistic regression model
In the GHS, 7.5% (1,124/15,010) of the study participants were by definition suffering from diabetes mellitus (9.5% males vs. 5.5% females). The vast majority of the diabetics (79.6%) had Type-II diabetes, 6.0% Type-I diabetes. We diagnosed gestational diabetes in 0.7% and diabetes after pancreatitis in 0.3%. The clinical classification was unclear in 13%.
Both fundus images and complete baseline-examination findings were available from 1,045 0f 1,124 (93.0%) of the diabetics.
Of the diabetics, 72.3% knew they had the disease. Most of them (42.8%) were taking an oral anti-diabetic, 17.0% required insulin, and 10.2% were taking both on combination therapy. Therapy was diet-based in 1.2%, while 1.1% were not on any therapy at the examination time point. In the questionnaire, 27.7% stated they did not have diabetes or were not taking any anti-diabetic medication (screening-detected disease).
Those in the study cohort with diabetes mellitus had an excessive Body Mass Index, BMI (Q1-/Q3-Median): 30.7 kg/m2 (27.3/34.3). The cohort's diabetics presented a median HbA1c value measuring 6.80% (6.40/7.30).
The total weighted prevalence of any DR in the group of diabetics from the city of Mainz and Mainz-Bingen region was 21.7%. Of the females, 22.6% and 21.1% of the males had DR.
The weighted prevalence of DMac was 2.3% in the group containing all the diabetics; 2.0% of the males versus 2.9% of the female diabetics presented diabetic ocular anomalies in the central retina.
The weighted prevalence of vision-threatening disease was 5.0%: 4.9% in the males and 5.1% in the females. Table 5 shows the prevalences of vision-threatening disease according to the patients' decades of age.
In the univariable analyses (Table 6) we identified an association of presence of DR (at any stage) with arterial hypertension (Odds Ratio [95% confidence interval]: 1.79 [1.174–2.719]; p = 0.0068) and duration of diabetes (1.08; 1.068–1.106; p<0.001). The remaining cardiovascular risk factors revealed no association with DR, neither with age nor with gender. The presence of revealed an association with duration of diabetes (1.16; 1.122–1.196; p<0001). We did, however, note a positive correlation between the stage of DR and HbA1c- and BMI values (Table 7). In the multivariable binary logistic regression analyses (Table 8) presence of DR (at any stage) was associated with age (0.97; 0.955–0.992; p = 0.0062), arterial hypertension (1.90; 1.190–3.044; p = 0.0072), and with diabetes duration (1.09; 1.068–1.114; p<0.0001), whereas presence of vision-threatening DR was associated with obesity (3.29; 1.504–7.206; p = 0.0029) and with duration of diabetes (1.18; 1.137–1.222; p<0.0001).
Odds ratios (OR) refer to overall diabetic retinopathy (DR) or to vision-threatening (DR).
The quality-control examinations revealed no vision-threatening disease in any control patient however, somewhat over 10% had retinal changes that would have been assessed as a mild stage of DR.
The GHS currently has the largest population-based study cohort in Germany to have ever been investigated in terms of the prevalence of diabetic retinopathy and maculopathy. Our study is thus delivering findings from the European country in with the largest population. We were astounded to learn that over a quarter of these individuals were unaware they had diabetes, revealing a high number of unreported cases of diabetes in Germany. These individuals cannot benefit from secondary prevention measures (which would help avoid the comorbidities associated with diabetes) because they are unknown of their disease. This does not just have consequences for the affected individual who—in a worse-case scenario—may go blind because of retinopathy. It could also create a heavy socioeconomic burden on the state due to high costs for disability.
Prevalence of diabetic retinopathy
About a fifth of the diabetics aged between 35 and 74 in this study were diagnosed with DR, with about a third of them presenting an advanced stage of the disease. Approximately a third of those affected were in a moderate, severe or even proliferative stage of the disease. Of the diabetics in the study cohort, 5% were threatened by vision loss. The GHS data therefore enables us to state that a quarter of a million persons in Germany (N = 257.600) are at risk of losing vision secondary to diabetes mellitus (0.32% of 80.5 million inhabitants) .
One of the key results of the GHS is our disclosure of a distressingly large number of unreported cases of diabetes mellitus in Germany and the relatively high prevalence of this vision-threatening disease in an industrial nation. Both results are economically and socially relevant, and will possibly incur drastic increases in healthcare costs. We report certain cardiovascular risk factors being associated with diabetic retinopathy, namely arterial hypertension and history of a myocardial infarction.
Table 9 summarises the prevalences of diabetic retinal and maculopathy and vision-threatening disease in the GHS in comparison with other population-based studies. In Europe data from large population-based cohorts with diabetes are available from the Netherlands  and Norway . The reported prevalences were somewhat higher than those in the GHS. A study from 2006 to 2008  delivered data from the USA as a western but non-European industrial nation. The prevalence of DR was 28.5% and thus a bit higher than in the GHS cohort. Diabetic maculopathy and vision-threatening disease were reported at 2.7% and 4.4% respectively being comparable to our results. Other more recent investigations on the epidemiology of diabetic retinopathy stem largely from Asian countries. Those studies from China [3,18] and Singapore  revealed prevalences much higher than ours. The lowest reported prevalence data are reported from the Indian (17.6%) and (19%) Arabic subcontinent [20,21].
The diversity of the data on prevalence can be attributed to typical influencing factors behind epidemiological studies. These are essentially ethnic background, environmental effects, genetic factors, and life style, as well as a study's methodology, i.e., its diagnostic criteria. In this study we based our DM diagnosis on the HbA1c value in those individuals whose disease was not previously known: in this case, diabetes was defined as an HbA1c value of 6.5% or higher . The application of other disease definitions based on fasting glucose values or an oral glucose-tolerance test may have revealed more or fewer diabetics in the GHS cohort and thus other prevalences. We based our disease definition on the HbA1c value because it is easy to assess, the assays are standardised, and because it is a widely-used parameter for diagnosing DM. Malkani and Mordes report in an overview article that one will identify fewer persons with diabetes mellitus using the HbA1c criteria compared to the conventional definition by blood glucose test . However, there appears to be ethnic differences as Jorgensen et al report in a comparative study between Danish and Inuit . Similarly results of the German KORA study show that there are certain differences in the number of diabetics when using the two different methods of diagnosis .
While the frequency of DM is influenced by the diagnostic criteria applied, technical and therapeutic factors play a role when determining the prevalence of diabetic retinal and macular diseases, as do diverse examination conditions. Optic coherence tomography (OCT) is a technical development that has revolutionised ophthalmological diagnostics, especially for macular diseases. OCT enables us to image the central retina in layers and to visualise and assess macular oedema . We did not have access to OCT images from our study cohort and thus cannot make any statements as to the presence or severity of diabetic macular oedema.
One possible reason for the underestimation of DR‘s prevalence revealed by our study is that we did not carry out medical pupil dilation. Nevertheless, our study methodology is comparable to other epidemiological investigations done under similar conditions, such as that by Zhang et al.  on the prevalence of DR in the United States. A recent review article shows that 14 out of 35 studies on diabetic retinopathy have not applied pupil dilation by medication . The relatively high percentage (>10%) of mild DR diagnosed in our control group can be attributed to the definition of DR (already present when a microaneurysm is visible), to image quality, and to other retinal microangiopathies. Yet not one patient was identified in the control group in a vision-threatening stage of the disease.
Moreover, it is conceivable that success in treating early stages of the disease will result in less severe manifestations of diabetic maculopathy in the future. For example, the recent introduction of intravitreal anti-VEGF therapy has improved the chances of preserving residual vision in patients with certain forms of diabetic maculopathy [27,28], and a recently-approved intravitreally-administered cortisone compound (fluocinolone acetonide) has delivered promising results even in patients with therapy-resistant diabetic macular oedema [29,30]. Further epidemiological studies are needed to assess the impact of new treatment options on prevention of vision loss secondary to diabetes mellitus.
Association between diabetic retinopathy and cardiovascular risk factors
There is still much work to be done in terms of prevention, patient care and public education because of the high rate of individuals unaware of their disease and because of DR’s association with other cardiovascular illnesses . In our study we discovered an association between the presence of DR and arterial hypertension and with the duration of diabetes in these persons. Furthermore, vision-threatening DR was associated with obesity. There is evidence of an association between DR and arterial hypertension [2,3,19] and dyslipidaemia [3,19]. Arterial hypertension plays a highly relevant role in the progression of retinopathy: the United Kingdom Prospective Diabetes Study demonstrated that the risk of DR progression can be reduced by about 34%, and the risk of a significant loss of visual acuity by even 47% in conjunction with a target blood pressure under 150/85 mmHg compared with one under 180/105 mmHg . It has been shown that obesity may possibly play an important role in endothelial dysfunction involved in the pathogenesis of DR . The association we observed between DR and arterial hypertension and obesity reinforces the acknowledged association between DR or diabetes, and (risk factors for) arteriosclerosis . Altered cardiometabolic risk profiles, and elevated blood pressure in particular, have shown to be significantly associated with chronic complications in overweight and obese patients with type 2 diabetes . This is in line with the association found between vision-threatening DR and obesity in persons with diabetes in the GHS. Furthermore, the association between obesity and vision-threatening DR might be explained by the fact that macular thickness and volume seem to be directly associated with higher serum lipid levels .
We were unable to address the Tromsø Eye Study  team‘s association between DR and microalbuminuria because the GHS examinations did not include testing that parameter. The GHS failed to detect any association between chronic renal insufficiency and DR.
The GHS’s responder rate was 60.2%. The extent to which potential immobility, inability or the poor vision of patients with diabetes may have prevented study participation (and thus influenced the prevalences we observed) cannot be evaluated (selection bias), as we have no access to such information.
Another limitation of the present study merits consideration: There might have been bias as this cohort potentially included some cases of prediabetic subjects who were treated with oral antidiabetic drugs (e. g., Metformin). It has been shown that Metformin decreases the rate of conversion from prediabetes to diabetes . Therefore, it might be that—according to the above-mentioned definition- we mis-classified some prediabetics to have a manifest DM. Nevertheless, as this prophylactic therapy is not recommended according to the Guidelines of the German Diabetes Association , we suppose that the number of prediabetic persons treated with off-label oral antidiabetic drugs was rather low. The results on the prevalence of DR in prediabetes have been published previously .
The prospective GHS is currently (since April 2012) in its 5-year follow-up phase during which study participants are being re-examined. We anticipate being able to deliver initial data on the incidence of diabetes mellitus and of DR later this year. Furthermore, we will be able to provide more detailed clinical information on any macular involvement thanks to OCT imaging being introduced to the GHS in the follow-up phase.
We are indebted to all study participants and all members of the Gutenberg Health Study, who are involved in the planning and conduct of this study.
Conceived and designed the experiments: AM NP PSW KAP. Performed the experiments: PR JL TP RH. Analyzed the data: A. Schneider A. Schulz KAP RH AM. Contributed reagents/materials/analysis tools: TP NP. Wrote the paper: PR JL KAP RH TP A. Schneider A. Schulz PSW NP AM.
- 1. Cheung N, Mitchell P, Wong TY (2010) Diabetic retinopathy. Lancet 376: 124–136. pmid:20580421
- 2. Zhang X, Saaddine JB, Chou CF, Cotch MF, Cheng YJ, Gleiss LS, et al. (2010) Prevalence of diabetic retinopathy in the United States, 2005–2008. Jama 304: 649–656. pmid:20699456
- 3. Xie XW, Xu L, Wang YX, Jonas JB (2008) Prevalence and associated factors of diabetic retinopathy. The Beijing Eye Study 2006. Graefes Arch Clin Exp Ophthalmol 246: 1519–1526. pmid:18604548
- 4. Yau JW, Rogers SL, Kawasaki R, Lamoureux EL, Kowalski JW, Bek T et al. (2012) Global prevalence and major risk factors of diabetic retinopathy. Diabetes Care 35: 556–564. pmid:22301125
- 5. Fletcher EL, Phipps JA, Ward MM, Puthussery T, Wilkinson-Berka JL (2007) Neuronal and glial cell abnormality as predictors of progression of diabetic retinopathy. Curr Pharm Des 13: 2699–2712. pmid:17897014
- 6. Fletcher EL, Phipps JA, Wilkinson-Berka JL (2005) Dysfunction of retinal neurons and glia during diabetes. Clin Exp Optom 88: 132–145. pmid:15926876
- 7. Gardner TW, Antonetti DA, Barber AJ, LaNoue KF, Nakamura M (2000) New insights into the pathophysiology of diabetic retinopathy: potential cell-specific therapeutic targets. Diabetes Technol Ther 2: 601–608. pmid:11469624
- 8. Lieth E, Gardner TW, Barber AJ, Antonetti DA (2000) Retinal neurodegeneration: early pathology in diabetes. Clin Experiment Ophthalmol 28: 3–8. pmid:11345341
- 9. Ly A, Yee P, Vessey KA, Phipps JA, Jobling AI, Fletcher EL (2011) Early inner retinal astrocyte dysfunction during diabetes and development of hypoxia, retinal stress, and neuronal functional loss. Invest Ophthalmol Vis Sci 52: 9316–9326. pmid:22110070
- 10. Vujosevic S, Midena E (2013) Retinal layers changes in human preclinical and early clinical diabetic retinopathy support early retinal neuronal and Muller cells alterations. J Diabetes Res 2013: 905058. pmid:23841106
- 11. Mirshahi A, Ponto KA, Hohn R, Wild PS, Pfeiffer N (2013) [Ophthalmological aspects of the Gutenberg Health Study (GHS): an interdisciplinary prospective population-based cohort study]. Ophthalmologe 110: 210–217. pmid:23504093
- 12. Wild PS, Zeller T, Beutel M, Blettner M, Dugi KA, Lackner KJ, et al. (2012) [The Gutenberg Health Study]. Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz 55: 824–829. pmid:22736163
- 13. Hoffmann EM, Lamparter J, Mirshahi A, Elflein H, Hoehn R, Wolfram C, et al. (2013) Distribution of central corneal thickness and its association with ocular parameters in a large central European cohort: the Gutenberg health study. PLoS One 8: e66158. pmid:23936291
- 14. (1991) Grading diabetic retinopathy from stereoscopic color fundus photographs—an extension of the modified Airlie House classification. ETDRS report number 10. Early Treatment Diabetic Retinopathy Study Research Group. Ophthalmology 98: 786–806. pmid:2062513
- 15. Bundesamt S Pressemitteilung Nr. 283 vom 27.08.2013: Available: https://www.destatis.de/DE/PresseService/Presse/Pressemitteilungen/2013/08/PD13_283_12411.html (Accessed 2013 August 27).
- 16. Stolk RP, Vingerling JR, de Jong PT, Dielemans I, Hofman A, Lamberts SW, et al. (1995) Retinopathy, glucose, and insulin in an elderly population. The Rotterdam Study. Diabetes 44: 11–15. pmid:7813804
- 17. Bertelsen G, Peto T, Lindekleiv H, Schirmer H, Solbu MD, Toft I, et al. (2013) Tromso eye study: prevalence and risk factors of diabetic retinopathy. Acta Ophthalmol 91: 716–721. pmid:22994366
- 18. Wang FH, Liang YB, Zhang F, Wang JJ, Wei WB, Tao QS, et al. (2009) Prevalence of diabetic retinopathy in rural China: the Handan Eye Study. Ophthalmology 116: 461–467. pmid:19168222
- 19. Wong TY, Cheung N, Tay WT, Wang JJ, Aung T, Saw SM, et al. (2008) Prevalence and risk factors for diabetic retinopathy: the Singapore Malay Eye Study. Ophthalmology 115: 1869–1875. pmid:18584872
- 20. Al-Maskari F, El-Sadig M (2007) Prevalence of diabetic retinopathy in the United Arab Emirates: a cross-sectional survey. BMC Ophthalmol 7: 11. pmid:17572909
- 21. Rema M, Premkumar S, Anitha B, Deepa R, Pradeepa R, Mohan V (2005) Prevalence of diabetic retinopathy in urban India: the Chennai Urban Rural Epidemiology Study (CURES) eye study, I. Invest Ophthalmol Vis Sci 46: 2328–2333. pmid:15980218
- 22. (2012) Diagnosis and classification of diabetes mellitus. Diabetes Care 35 Suppl 1: S64–71. pmid:22187472
- 23. Malkani S, Mordes JP (2011) Implications of using hemoglobin A1C for diagnosing diabetes mellitus. Am J Med 124: 395–401. pmid:21531226
- 24. Jorgensen ME, Bjerregaard P, Borch-Johnsen K, Witte D (2010) New diagnostic criteria for diabetes: is the change from glucose to HbA1c possible in all populations? J Clin Endocrinol Metab 95: E333–336. pmid:20739381
- 25. Rathmann W, Kowall B, Tamayo T, Giani G, Holle R, Thorand B, et al. (2012) Hemoglobin A1c and glucose criteria identify different subjects as having type 2 diabetes in middle-aged and older populations: the KORA S4/F4 Study. Ann Med 44: 170–177. pmid:21091229
- 26. Bandello F, Pognuz R, Polito A, Pirracchio A, Menchini F, Ambesi M (2003) Diabetic macular edema: classification, medical and laser therapy. Semin Ophthalmol 18: 251–258. pmid:15513012
- 27. Do DV, Nguyen QD, Khwaja AA, Channa R, Sepah YJ, Sophie R, et al. (2013) Ranibizumab for edema of the macula in diabetes study: 3-year outcomes and the need for prolonged frequent treatment. JAMA Ophthalmol 131: 139–145. pmid:23544200
- 28. Mitchell P, Bandello F, Schmidt-Erfurth U, Lang GE, Massin P, Schlingemann RO, et al. (2011) The RESTORE study: ranibizumab monotherapy or combined with laser versus laser monotherapy for diabetic macular edema. Ophthalmology 118: 615–625. pmid:21459215
- 29. Sanford M (2013) Fluocinolone acetonide intravitreal implant (Iluvien(R)): in diabetic macular oedema. Drugs 73: 187–193. pmid:23335133
- 30. Thomas BJ, Shienbaum G, Boyer DS, Flynn HW Jr. (2013) Evolving strategies in the management of diabetic macular edema: clinical trials and current management. Can J Ophthalmol 48: 22–30. pmid:23419295
- 31. Furthauer J, Flamm M, Sonnichsen A (2013) Patient and physician related factors of adherence to evidence based guidelines in diabetes mellitus type 2, cardiovascular disease and prevention: a cross sectional study. BMC Fam Pract 14: 47. pmid:23557543
- 32. (1998) Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. UK Prospective Diabetes Study Group. Bmj 317: 703–713. pmid:9732337
- 33. Tomic M, Ljubic S, Kastelan S, Gverovic Antunica A, Jazbec A, Poljicanin T (2013) Inflammation, haemostatic disturbance, and obesity: possible link to pathogenesis of diabetic retinopathy in type 2 diabetes. Mediators Inflamm 2013: 818671. pmid:24363502
- 34. Cheung N, Wang JJ, Klein R, Couper DJ, Sharrett AR, Wong TY (2007) Diabetic retinopathy and the risk of coronary heart disease: the Atherosclerosis Risk in Communities Study. Diabetes Care 30: 1742–1746. pmid:17389333
- 35. Cheng Y, Zhang H, Chen R, Yang F, Li W, Chen L, et al. (2014) Cardiometabolic risk profiles associated with chronic complications in overweight and obese type 2 diabetes patients in South China. PLoS One 9: e101289. pmid:24992024
- 36. Sasaki M, Kawashima M, Kawasaki R, Uchida A, Koto T, Shinoda H, et al. (2014) Association of serum lipids with macular thickness and volume in type 2 diabetes without diabetic macular edema. Invest Ophthalmol Vis Sci 55: 1749–1753. pmid:24569581
- 37. Lily M, Godwin M (2009) Treating prediabetes with metformin: systematic review and meta-analysis. Can Fam Physician 55: 363–369. pmid:19366942
- 38. Matthaei S, Bierwirth R, Fritsche A, Gallwitz B, Haring HU, Joost HG, et al. (2009) Medical antihyperglycaemic treatment of type 2 diabetes mellitus: update of the evidence-based guideline of the German Diabetes Association. Exp Clin Endocrinol Diabetes 117: 522–557. pmid:19876795
- 39. Lamparter J, Raum P, Pfeiffer N, Peto T, Hohn R, Elflein H, et al. (2014) Prevalence and associations of diabetic retinopathy in a large cohort of prediabetic subjects: the Gutenberg Health Study. J Diabetes Complications 28: 482–487. pmid:24630763
- 40. Mitchell P, Smith W, Wang JJ, Attebo K (1998) Prevalence of diabetic retinopathy in an older community. The Blue Mountains Eye Study. Ophthalmology 105: 406–411. pmid:9499768